Results 211 to 220 of about 677,670 (306)

Correction: Phosphoglycerate dehydrogenase promotes pancreatic cancer development by interacting with eIF4A1 and eIF4E

Journal of Experimental & Clinical Cancer Research
Xuhui Ma, Boya Li, Jie Liu, Yan Fu, Yongzhang Luo   +4 more
doaj   +1 more source

Optimizing longifolene production in Yarrowia lipolytica via metabolic and protein engineering. [PDF]

Synth Syst Biotechnol
Yao YT, Zhang X, Wang CY, Zhang YH, Li DW, Yang WD, Li HY, Zou LG.   +7 more
europepmc   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Protein engineering using variational free energy approximation. [PDF]

Nat Commun
Lobzaev E, Herrera MA, Kasprzyk M, Stracquadanio G.   +3 more
europepmc   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

A suite of pre-assembled, pET28b-based Golden Gate vectors for efficient protein engineering and expression. [PDF]

Protein Sci
Gaur D, Wohlever ML.
europepmc   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

From Llms to Sustainable Proteins: Fine-Tuning and Prompt Engineering for Multi-Agent Ai in Waste Carbon-Utilising Microbial Protein Production

Alexander D. Kalian, Jaewook Lee, S. Johannesson, Lennart Otte, Christer Högstrand, Miao Guo   +5 more
openalex   +1 more source

Targeting p38α in cancer: challenges, opportunities, and emerging strategies

Molecular Oncology, EarlyView.
p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley   +1 more source

Computational epitope profiling and AI-driven protein engineering enable rational design of multi-epitope vaccines against <i>Mycobacterium tuberculosis</i>. [PDF]

Comput Struct Biotechnol J
Li X, Tao X, Zhong M, Wang Y, Xue H, Andongma BT, Chou SH, Wei H, He J, Yang H.   +9 more
europepmc   +1 more source